GRAIL Corp (GRAL) - Expected earnings per share growth for next year

GRAIL (GRAL) - corporate logo

A team of top oncologists at GRAIL, Inc. (GRAL) is developing breakthrough diagnostic methods. The company's sector leadership is underpinned by massive R&D barriers and a unique multi-cancer screening dataset. A revision in the consensus earnings per share forecast confirms this positioning, where the -2.80 mark reflects the latest data. Processes are being automated through the implementation of AI algorithms and robotic blood sequencing platforms.

GRAIL Inc (GRAL): Consensus forecast of earnings per share growth for next year from 06/29/2024 to 11/12/2026

GRAL (grail.com): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart GRAIL Corp|GRAL - Price Target Chart
- market capitalization indicators:
Market Valuation GRAIL|GRAL - Total Enterprise Value
- book capitalization information:
Net Assets per Single Share GRAIL|GRAL - Book Valuation of Business|Market Capitalization to Book Value Ratio grail.com|GRAL - Company Total Asset Base
- issuer credit burden and liquidity indicators:
Debt to Equity GRAIL, Inc.|GRAL - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital GRAIL|GRAL - Company Total Indebtedness|Debt to Book Capitalization Ratio GRAIL|GRAL - Company Long-Term Loans and Borrowings|Company Short-Term Debts GRAIL|Quick Ratio grail.com
- net income and valuation ratios data:
GRAL - Net Financial Result|Expected Profit GRAIL, Inc.|GRAL - Price to Earnings Ratio|Projected Price to Earnings GRAIL, Inc.|GRAL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple GRAIL|GRAL - Operating income before deduction of amortization|Earnings per share for the last twelve months GRAIL|GRAL - Earnings per share for the last 12 months|Quarterly EPS earnings growth grail.com|GRAL - Net earnings per share growth this year|Expected earnings per share growth for next year GRAIL, Inc.
Analysis of all company metrics:GRAL, GRAIL Corp
Core merchandise of grail.com

For GRAIL, Inc. (GRAL), the consensus EPS growth rate for the coming year reflects the updated management's ability to convert the scientific potential of early cancer detection into tangible financial results. This chart measures the percentage change in expected earnings per share, allowing investors to assess the accuracy of commercialization models and avoid purchasing the asset at its peak following the release of financial reports.

Competitor analysis for GRAIL, Inc.

Net earnings per share growth forecast for next year Caris|Net earnings per share growth forecast for next year GH|Expected earnings per share growth for next year VCYT (Veracyte, Inc.)|CELC - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Myriad Genetics MYGN|Consensus forecast of earnings per share growth for next year Castle Biosciences Inc (CSTL)|Burning Rock Biotech Ltd. - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year VolitionRx Limited VNRX|Biodesix, Inc. (BDSX) - Net earnings per share growth forecast for next year|PRPO - Consensus forecast of earnings per share growth for next year|CHEK (Check-Cap Ltd) - Earnings growth forecast for next year|MYNZ - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year OncoCyte Corp. (OCX)